Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1HP in adults with tuberculosis infection
ChiCTR2400089896Phase 4Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of isoniazid and rifapentine in Tuberculosis (TB) and latent tuberculosis infection (LTBI), sponsored by Shenzhen Third People's Hospital. Primary endpoints: Treatment completion rate, Incidence rate of grade 3-4 adverse events and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
isoniazidrifapentine
03
Conditions
Tuberculosis (TB)latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ChiCTR2400089896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089896.